home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

34.02 -4.07 (-10.69%)

Official Closing Price Updated: 7:00 PM EDT, Apr 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region

February 13, 2025

From QIAGEN N.V.

Via Business Wire

Qiagen Earnings Review: Q4 Summary ↗

February 05, 2025

Via Benzinga

Qiagen: Q4 Earnings Insights ↗

February 05, 2025

Via Benzinga

QIAGEN delivers solid Q4 2024 growth ahead of outlook

February 05, 2025

From QIAGEN N.V.

Via Business Wire

Earnings Scheduled For February 5, 2025 ↗

February 05, 2025

Via Benzinga

Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗

April 29, 2024

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.

Via Benzinga

Topics Stocks

Earnings Scheduled For February 6, 2024 ↗

February 06, 2024

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.

Via Benzinga

Earnings Preview: Qiagen ↗

February 05, 2024

Via Benzinga

QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent

February 04, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million

January 16, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

January 15, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

January 12, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples

January 10, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care

January 09, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content

January 07, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data

December 12, 2024

From QIAGEN N.V.

Via Business Wire

QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation

December 05, 2024

From QIAGEN N.V.

Via Business Wire

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

November 28, 2024

From QIAGEN N.V.

Via Business Wire

18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker' ↗

October 10, 2024

Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500.

Via Benzinga

Topics Stocks

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

August 06, 2024

From Myriad Genetics, Inc.

Via GlobeNewswire

Strategic Buy Lights Up This Biotech Stock: Time to Invest?

July 16, 2024

Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences.

Via MarketBeat

FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation ↗

June 24, 2024

The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with KRASG12C-mutated advanced or metastatic colorectal cancer.

Via Benzinga

Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 20, 2024

Via Benzinga

Qiagen Unveils Plan For $1B Shareholder Returns, Major Product Launches ↗

June 17, 2024

QIAGEN announces a comprehensive growth strategy by 2028. The plan includes significant shareholder returns, new product launches, and a focus on digital and diagnostic advancements.

Via Benzinga

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

May 30, 2024

From Myriad Genetics, Inc.

Via GlobeNewswire

QGEN Stock Earnings: Qiagen Beats EPS, Beats Revenue for Q1 2024 ↗

April 29, 2024

QGEN stock results show that Qiagen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

US Stocks Set To Approach New Week With Caution Ahead Of Fed Meeting, Tech Earnings: Analyst Says 'Buy The Dip' Contingent On This Condition ↗

April 29, 2024

U.S. stocks are looking to build on past week’s gains, with the mood remaining cautiously optimistic. The major index futures were modestly higher in early trading.

Via Benzinga

Topics Economy

Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report ↗

May 06, 2024

According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far.

Via Benzinga

Topics Stocks

US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday? ↗

April 29, 2024

U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc....

Via Benzinga

Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion ↗

January 17, 2024

Goldman Sachs upgrades Twist Bioscience as Express Genes launch addresses SynBio division's gross margin issues. With 5-7 days gene delivery, TWST taps into a previously inaccessible market, enhancing...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com